Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

9 Mar 2018

Abstract excerpt

Abstract While high-grade serous ovarian carcinoma (HGSOC) is the most common histologic subtype of ovarian cancer, significant tumor heterogeneity exists. In addition, chemotherapy induces changes in gene expression and alters the mutational profile. To evaluate the notion that patients with HGSOC could be better classified for optimal treatment based on gene expression, we compared genetic variants [by DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related molecular mechanisms research
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29523763
DOI: 10.1158/1541-7786.mcr-17-0594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian CarcinomaPMID 29523763Read ↗

Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategiesSemantic proximity Read ↗

Biological Insights into Chemotherapy Resistance in Ovarian CancerSemantic proximity Read ↗

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patientsSemantic proximity Read ↗

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.Semantic proximity Read ↗

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

Neoadjuvant Chemotherapy Modulates the Tumor Microenvironment in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity Read ↗

Comprehensive Genomic Characterization in Ovarian Low-Grade and Chemosensitive and Chemoresistant High-Grade Serous Carcinomas.Semantic proximity Read ↗

Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.Semantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapySemantic proximity Read ↗

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.